Testosterone therapy and the risk of cardiovascular disease in older, hypogonadal men.

The TRAVERSE trial, as the first RCT powered to assess CVD events, did not show increased major adverse cardiac events (MACE) incidence with testosterone therapy.

• The TRAVERSE trial is described as 'the first RCT powered to assess CVD events'
• Limitations identified include maintenance of testosterone at low-normal levels, a high participant discontinuation rate, and short follow-up
• These limitations 'warrant a careful interpretation of its results'
• The trial specifically examined hypogonadal men with or at increased risk for cardiovascular disease

The TTrials cardiovascular sub-study showed an increase in non-calcified coronary plaque with testosterone therapy.

• The finding of increased non-calcified plaque was identified in the TTrials cardiovascular sub-study
• This finding is described as indicating 'the need for ongoing research into the long-term CV impact of TT'
• Non-calcified plaque is considered a marker of potentially vulnerable atherosclerotic disease
• This result was highlighted as a key concern requiring further investigation

Observational studies have variably linked low endogenous testosterone levels with increased cardiovascular disease risk.

• The association between low endogenous testosterone and CVD risk was described as 'variable' across observational studies
• The review examined CV implications within the context of aging, obesity, and endogenous sex hormones
• No consistent directional finding was reported across all observational studies
• These findings informed but did not resolve the debate over CV safety of testosterone therapy

Randomized controlled trials demonstrate that testosterone therapy yields cardiometabolic benefits without increasing short-term cardiovascular risk.

• RCTs are distinguished from observational studies in showing cardiometabolic benefits
• The cardiometabolic benefits were noted without increasing 'short-term CV risk'
• The qualifier 'short-term' suggests long-term CV risk remains uncertain
• This finding supports a nuanced interpretation rather than a blanket safety or risk conclusion

Diverging safety recommendations and clinical guidelines exist worldwide regarding the cardiovascular implications of testosterone therapy.

• The review describes 'diverging safety recommendations and clinical guidelines worldwide'
• This divergence motivated the synthesis and critical evaluation of long-term studies
• The review covers effects of TT within the context of aging, obesity, and endogenous sex hormones
• The goal was 'to support informed clinical decision-making'

Clinical practice should prioritize individualized care and informed discussions on the potential cardiovascular implications of testosterone therapy until more definitive evidence is available.

• The recommendation applies particularly to 'older men with known CVD'
• Current evidence gaps are specifically cited as the reason for this cautious approach
• The CV effects of 'maintaining physiological testosterone levels through exogenous means remain to be fully explored'
• The decision to initiate TT should 'consider the current evidence gaps'